SCHEMBL9604424

SCHEMBL9604424

CC(=O)OCC1OC(OCCCCC(=O)OCc2ccccc2)C(C)C(C)C1C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
LMNA P02545 3/20 0.42
KMT2A Q03164 1/20 0.41
MAPK1 P28482 3/20 0.38
CYP2D6 P10635 2/20 0.38
LGALS8 O00214 1/20 0.38
TSHR P16473 3/20 0.37
EPHX2 P34913 1/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CASP1 P29466 1/20 0.35
TNF P01375 1/20 0.34
FAAH O00519 1/20 0.34
MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16248647 1.00 ALDH1A1 (0.42) ALDH1A1LMNAKMT2AMAPK1CYP2D6
SCHEMBL17589419 0.99 ALDH1A1 (0.41) ALDH1A1LMNAKMT2AMAPK1CYP2D6
SCHEMBL16248755 0.93 ALDH1A1 (0.45) ALDH1A1LMNAKMT2AMAPK1CYP2D6
SCHEMBL26481973 0.90 LMNA (0.48) ALDH1A1LMNAKMT2AMAPK1CYP2D6
SCHEMBL10226142 0.90 TDP1 (0.42) ALDH1A1LMNAKMT2AMAPK1LGALS8
SCHEMBL9604623 0.90 TDP1 (0.42) ALDH1A1LMNAKMT2AMAPK1LGALS8
SCHEMBL15829782 0.90 TDP1 (0.42) ALDH1A1LMNAKMT2AMAPK1LGALS8
SCHEMBL27416860 0.89 LMNA (0.48) ALDH1A1LMNAKMT2AMAPK1CYP2D6
SCHEMBL19500413 0.89 LMNA (0.49) ALDH1A1LMNAKMT2AMAPK1CYP2D6
SCHEMBL16248678 0.88 LMNA (0.43) ALDH1A1LMNAKMT2AMAPK1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303618-A1 TRIPTOLIDE CONJUGATES AND USES THEREOF REYOUNG CORPORATION (US) 2023-09-28 US disclosed
US-11666653-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2023-06-06 US disclosed
US-9867882-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2018-01-16 US disclosed
US-9814777-B2 Targeting lipids ARBUTUS BIOPHARMA CORPORATION (CA) 2017-11-14 US disclosed
US-20160375137-A9 TARGETING LIPIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-12-29 US disclosed
US-9370581-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 US disclosed
US-9370582-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 US disclosed
US-9352048-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9290760-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-03-22 US disclosed
US-20150203847-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION ALNYLAM PHARMACEUTICALS INC (US) 2015-07-23 US disclosed
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 US disclosed
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 US disclosed
US-8962580-B2 Chemical modifications of monomers and oligonucleotides with cycloaddition ALNYLAM PHARMACEUTICALS, INC. (US) 2015-02-24 US disclosed
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-01-08 US disclosed
US-8828956-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2014-09-09 US disclosed
US-20140179761-A1 TARGETING LIPIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2014-06-26 US disclosed
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2013-07-11 US disclosed
US-8450467-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2012-05-31 US disclosed
US-20120035115-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION ALNYLAM PHARMACEUTICALS, INC. (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203847-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION DNMT1, LCK, MCTS1 ALDH1A1 848/4885LMNA 4253/4885KMT2A 632/4885
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC ALDH1A1 4231/4885LMNA 266/4885KMT2A 2791/4885
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC ALDH1A1 4381/4885LMNA 271/4885KMT2A 2713/4885
US-20140179761-A1 TARGETING LIPIDS LY96, ABHD10, APOB ALDH1A1 1600/4885LMNA 169/4885KMT2A 1322/4885
US-11666653-B2 Carbohydrate conjugates as delivery agents for oligonucleotides HAVCR2, B3GAT3, CSGALNACT1 ALDH1A1 3484/4885LMNA 1934/4885KMT2A 1352/4885
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC ALDH1A1 4251/4885LMNA 274/4885KMT2A 2797/4885
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC ALDH1A1 4251/4885LMNA 274/4885KMT2A 2797/4885
US-20120035115-A1 CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION DNMT1, LCK, MCTS1 ALDH1A1 848/4885LMNA 4253/4885KMT2A 632/4885
US-20230303618-A1 TRIPTOLIDE CONJUGATES AND USES THEREOF TLR9, XIAP, ENPP2 ALDH1A1 826/4885LMNA 3157/4885KMT2A 3005/4885
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC ALDH1A1 4231/4885LMNA 266/4885KMT2A 2791/4885
US-20160375137-A9 TARGETING LIPIDS LY96, ABHD10, APOB ALDH1A1 1600/4885LMNA 169/4885KMT2A 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.